What is CJC-1295 DAC peptide?
CJC-1295 DAC is a synthetic analog of growth hormone-releasing hormone (GHRH) that enhances plasma levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Drug affinity complex (DAC) is an additive component that helps to prolong the half-life of CJC-1295 in plasma.
CJC-1295 DAC SPECIFICATIONS
AKA: CJC 1295 with DAC
Molecular Formula: C152H252N44O42
Molecular Weight: 3647.954 g/mol
PubChem: CID 56841945
Researchers have created several synthetic modifications of growth hormone-releasing hormone (GHRH), which retain certain selective traits of the hormone while eliminating others. CJC-1295 happens to be one of such synthetic analogs that comprise the first 29 amino acids of GHRH.Interestingly, it happens to be a maleimide derivative of 1-29 residues of hGRF. This helps produce a GH secretagogue with greater solubility, which is easier to synthesize in larger volumes and maintains the biological effects of GH.
CJC 1295 Versus CJC-1295 DAC
CJC-1295 DAC shares similarities with other GHRH analogs like Sermorelin, as both are derivatives of the first 29 amino acids of GHRH. It is also closest to, but not identical, to modified GRF (1-29). The similarity and the fact that CJC-1295 was created along with DAC creates confusion between the peptides.
Through a lysine linker, DAC is attached to CJC-1295 to protect the peptide during its circulation in the bloodstream. DAC facilitates the association of peptides with blood proteins such as albumin. This enhances their half-life compared to similar peptides such as GRF (1-29). DAC conjugated CJC-1295 was addressed as only CJC-1295 by Conjuchem Biotechnologies, the company that developed DAC. The non-DAC conjugated variant of the peptide being also available under the same name led to confusion between the two varieties.
CJC-1295 and Growth Hormone Release
The peptide triggers the release of GH as it is a synthetic analog for the natural GHRH. Mice models have shown that a single administration of the peptide can induce almost 2-10 times higher production of GH. GH expression reaches maximum level after 2 hours of the peptide administration, and the effect is maintained up to about six days later. The peptide maintains the natural physiological level of GH, unlike other secretagogues. In other words, CJC-1295 acts as a physiological GHRH and helps maintain the natural biological high and low expression pattern in GH levels.
CJC-1295 maintains the physiological level of the hormone while enhancing its release in the blood. This ensures that GH brings about the benefits without enhancing its adverse side effects. CJC-1295 has been shown to maintain the physiological regulation of GH on protein synthesis, fat metabolism, blood sugar, hypertrophy, bone density, hyperplasia, and myocardial function.
CJC-1295 and Infertility
Studies from the early 1990s indicate that CJC-1295 and other GRF analogs can improve female infertility. Mice models of superovulation have proven that GH and IGF-1 levels increase in blood around the time of ovulation. Thus the treatment, including CJC-1295 and GRF analogs can promote ovulation in female patients, possibly through IGF-1 and GH expression cycle. The use of GH secretagogues like CJC-1295 is sufficient to promote proper ovulation. Scientists have further suggested the use of these analogs to improve sperm production and thus treat male infertility through proper research is required to test the hypothesis.
Research has highlighted that it can restore the physiological release of GH in mice lacking normal GH physiology. Therefore the peptide can be potentially used to treat growth anomalies in different mammalian species, including human beings. Maintenance of the circadian cycle of GH release happens to be crucial to bringing about appropriate production of downstream hormones, such as insulin-like growth factor-1 (IGF-1).
CJC-1295 DAC Peptide Summary
CJC-1295 is a growth hormone secretagogue that has been developed to possess a long half-life in plasma. It helps restore and maintain the inherent physiologic expression rhythm of GH. The molecule has achieved both the objectives with which it was created. However, it has been of less interest to researchers due to the prevalence of number of such hormone analogs and the proprietorship on the molecule structure. Interestingly, now as it can be manufactured at will, the peptide is expected to renew research interest, especially owing to its potential in infertility treatment.
It has shown mild adverse effects, low oral and fantastic subcutaneous availability in mice models. However, the dose administered to mice (per kg) does not scale up for human use.